Search

Your search keyword '"Weng, Lihong"' showing total 174 results
Start Over Author "Weng, Lihong"
174 results on '"Weng, Lihong"'

2. Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma

Author

Barish, Michael E, Weng, Lihong, Awabdeh, Dina, Zhai, Yubo, Starr, Renate, D'Apuzzo, Massimo, Rockne, Russell C, Li, Haiqing, Badie, Behnam, Forman, Stephen J, and Brown, Christine E

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Clinical Research, Vaccine Related, Brain Disorders, Immunization, Brain Cancer, Rare Diseases, Development of treatments and therapeutic interventions, 5.2 Cellular and gene therapies, Cell Line, Tumor, ErbB Receptors, Glioblastoma, Glioma, Humans, Immunotherapy, Immunotherapy, Adoptive, Interleukin-13 Receptor alpha2 Subunit, Receptors, Antigen, T-Cell, T-Lymphocytes, Xenograft Model Antitumor Assays, tumor heterogeneity, spatial organization of glioblastoma, antigen escape, immunotherapy, CART cells, IL13R alpha 2, HER2, EGFR, CAR T cells, IL13Rα2, Clinical Sciences, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

High-grade (WHO grades III-IV) glioma remains one of the most lethal human cancers. Adoptive transfer of tumor-targeting chimeric antigen receptor (CAR)-redirected T cells for high-grade glioma has revealed promising indications of anti-tumor activity, but objective clinical responses remain elusive for most patients. A significant challenge to effective immunotherapy is the highly heterogeneous structure of these tumors, including large variations in the magnitudes and distributions of target antigen expression, observed both within individual tumors and between patients. To obtain a more detailed understanding of immunotherapy target antigens within patient tumors, we immunochemically mapped at single cell resolution three clinically-relevant targets, IL13Rα2, HER2 and EGFR, on tumor samples drawn from a 43-patient cohort. We observed that within individual tumor samples, expression of these antigens was neither random nor uniform, but rather that they mapped into local neighborhoods - phenotypically similar cells within regions of cellular tumor - reflecting not well understood properties of tumor cells and their milieu. Notably, tumor cell neighborhoods of high antigen expression were not arranged independently within regions. For example, in cellular tumor regions, neighborhoods of high IL13Rα2 and HER2 expression appeared to be reciprocal to those of EGFR, while in areas of pseudopalisading necrosis, expression of IL13Rα2 and HER2, but not EGFR, appeared to reflect the radial organization of tumor cells around hypoxic cores. Other structural features affecting expression of immunotherapy target antigens remain to be elucidated. This structured but heterogeneous organization of antigen expression in high grade glioma is highly permissive for antigen escape, and combinatorial antigen targeting is a commonly suggested potential mitigating strategy. Deeper understanding of antigen expression within and between patient tumors will enhance optimization of combination immunotherapies, the most immediate clinical application of the observations presented here being the importance of including (wild-type) EGFR as a target antigen.

Published
2022

6. High expression of AlkB homolog 5 suppresses the progression of non‐small cell lung cancer by facilitating ferroptosis through m6A demethylation of SLC7A11.

Author

Huang, Zhangzhou, Lin, Gen, Hong, Yaping, Weng, Lihong, Zhu, Kai, and Zhuang, Wu

Subjects
NON-small-cell lung carcinoma, GLUTAMATE transporters, GLUTATHIONE peroxidase, DEMETHYLATION, REACTIVE oxygen species
Abstract

Objective: Non‐small cell lung cancer (NSCLC) is a prevailing LC characterized by poor outcomes. AlkB homolog 5 (ALKBH5) functions as a tumor suppressor in several cancers. This study delved into the role of ALKBH5 in NSCLC development. Methods: TCGA database predicted ALKBH5 expression in NSCLC patients. ALKBH5 levels in NSCLC and human bronchial epithelial cells were determined. pcDNA3.1‐ALKBH5/NC, pcDNA3.1‐SLC7A11/NC, and ferrostatin‐1 were used to explore the interactions among ALKBH5, SLC7A11, and ferroptosis. SLC7A11 mRNA and its protein levels were measured by RT‐qPCR and Western blot. Cell viability, apoptosis, migration, and invasion were assessed by CCK‐8, flow cytometry, and Transwell. Total N6‐methyladenosine (m6A) quantification and its enrichment on SLC7A11 mRNA were determined, followed by the observation of Ki67, ALKBH5 and SLC7A11‐positive cell numbers. Glutathione (GSH), lipid reactive oxygen species (lipid‐ROS), malondialdehyde (MDA), and iron ion contents were determined. Animal experiments further analyzed the role of ALKBH5 in tumor development and glutathione peroxidase 4 (GPX4) expression. Results: Bioinformatics analysis revealed the lowly‐expressed ALKBH5 in LC patients. ALKBH5 was downregulated in NSCLC cells and its upregulation repressed proliferation activity, invasion, and migration, and facilitated apoptosis. ALKBH5 upregulation decreased GSH, increased lipid‐ROS, MDA, and iron ion contents, and downregulated SLC7A11 by reducing m6A modification. SLC7A11 upregulation partly annulled the effect of ALKBH5 overexpression on cell ferroptosis and malignant behaviors. In vivo assays elucidated the suppression of ALKBH5 upregulation on tumor development and GPX4 levels. Conclusion: ALKBH5 upregulation downregulates SLC7A11 transcription by decreasing m6A modification, thus promoting NSCLC cell ferroptosis and ultimately repressing NSCLC progression. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. P-136 Phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma

Author

Du, Juan, primary, Qiang, Wanting, additional, Lu, Jing, additional, Jia, Yanchun, additional, He, Haiyan, additional, Liu, Jin, additional, Guo, Pei, additional, Yang, Ying, additional, Feng, Zhongyuan, additional, Jin, Lina, additional, Fan, Xiaoqiang, additional, Liu, Jia, additional, Zhang, Qi, additional, Shen, Lianjun, additional, Weng, Lihong, additional, Li, Wenling, additional, and Cao, Wei, additional

Published
2023
Full Text
View/download PDF

10. S234: UPDATED CLINICAL RESULTS OF FIRST-IN-HUMAN STUDY OF CD19/BCMA DUAL-TARGETING FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA

Author

Chen, Xinfeng, primary, Ping, Yu, additional, LI, Ling, additional, Zhang, Lei, additional, Zhang, Xudong, additional, Huang, Jianmin, additional, Liu, Jia, additional, LI, Gui, additional, He, Jiaping, additional, Zhang, Hua, additional, Zhao, Wei, additional, Weng, Lihong, additional, Yin, Wenjie, additional, Shen, Lianjun, additional, Cao, Wei William, additional, LI, Wenling, additional, Zhang, Mingzhi, additional, and Zhang, Yi, additional

Published
2023
Full Text
View/download PDF

11. P869: UPDATED RESULTS OF A PHASE I, OPEN-LABEL STUDY OF BCMA/CD19 DUAL-TARGETING FASTCAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Author

Du, Juan, primary, Fu, Weijun, additional, Jiang, Hua, additional, Dong, Baoxia, additional, Gao, LI, additional, Liu, LI, additional, Ge, Jian, additional, He, Aili, additional, LI, Lu, additional, Lu, Jing, additional, Chen, Xiequn, additional, Liu, Jia, additional, Zhang, Qi, additional, He, Jiaping, additional, Weng, Lihong, additional, Zhang, Hua, additional, Shen, Lianjun, additional, Cao, Wei, additional, and LI, Wenling, additional

Published
2023
Full Text
View/download PDF

13. Data from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma

Author

Wang, Xiuli, primary, Huynh, Christian, primary, Urak, Ryan, primary, Weng, Lihong, primary, Walter, Miriam, primary, Lim, Laura, primary, Vyas, Vibhuti, primary, Chang, Wen-Chung, primary, Aguilar, Brenda, primary, Brito, Alfonso, primary, Sarkissian, Aniee, primary, Bandara, N. Achini, primary, Yang, Lu, primary, Wang, Jinhui, primary, Wu, Xiwei, primary, Zhang, Jianying, primary, Priceman, Saul J., primary, Qin, Hong, primary, Kwak, Larry W., primary, Budde, Lihua E., primary, Thomas, Sandra H., primary, Clark, Mary C., primary, Popplewell, Leslie, primary, Siddiqi, Tanya, primary, Brown, Christine E., primary, and Forman, Stephen J., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figures from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma

Author

Wang, Xiuli, primary, Huynh, Christian, primary, Urak, Ryan, primary, Weng, Lihong, primary, Walter, Miriam, primary, Lim, Laura, primary, Vyas, Vibhuti, primary, Chang, Wen-Chung, primary, Aguilar, Brenda, primary, Brito, Alfonso, primary, Sarkissian, Aniee, primary, Bandara, N. Achini, primary, Yang, Lu, primary, Wang, Jinhui, primary, Wu, Xiwei, primary, Zhang, Jianying, primary, Priceman, Saul J., primary, Qin, Hong, primary, Kwak, Larry W., primary, Budde, Lihua E., primary, Thomas, Sandra H., primary, Clark, Mary C., primary, Popplewell, Leslie, primary, Siddiqi, Tanya, primary, Brown, Christine E., primary, and Forman, Stephen J., primary

Published
2023
Full Text
View/download PDF

15. Supplemental Table 3 from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma

Author

Wang, Xiuli, primary, Walter, Miriam, primary, Urak, Ryan, primary, Weng, Lihong, primary, Huynh, Christian, primary, Lim, Laura, primary, Wong, ChingLam W., primary, Chang, Wen-Chung, primary, Thomas, Sandra H., primary, Sanchez, James F., primary, Yang, Lu, primary, Brown, Christine E., primary, Pichiorri, Flavia, primary, Htut, Myo, primary, Krishnan, Amrita Y., primary, and Forman, Stephen J., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure S3 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

Author

Brown, Christine E., primary, Badie, Behnam, primary, Barish, Michael E., primary, Weng, Lihong, primary, Ostberg, Julie R., primary, Chang, Wen-Chung, primary, Naranjo, Araceli, primary, Starr, Renate, primary, Wagner, Jamie, primary, Wright, Christine, primary, Zhai, Yubo, primary, Bading, James R., primary, Ressler, Julie A., primary, Portnow, Jana, primary, D'Apuzzo, Massimo, primary, Forman, Stephen J., primary, and Jensen, Michael C., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Tables S1-3 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

Author

Brown, Christine E., primary, Badie, Behnam, primary, Barish, Michael E., primary, Weng, Lihong, primary, Ostberg, Julie R., primary, Chang, Wen-Chung, primary, Naranjo, Araceli, primary, Starr, Renate, primary, Wagner, Jamie, primary, Wright, Christine, primary, Zhai, Yubo, primary, Bading, James R., primary, Ressler, Julie A., primary, Portnow, Jana, primary, D'Apuzzo, Massimo, primary, Forman, Stephen J., primary, and Jensen, Michael C., primary

Published
2023
Full Text
View/download PDF

18. Supplemental Figures from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma

Author

Wang, Xiuli, primary, Walter, Miriam, primary, Urak, Ryan, primary, Weng, Lihong, primary, Huynh, Christian, primary, Lim, Laura, primary, Wong, ChingLam W., primary, Chang, Wen-Chung, primary, Thomas, Sandra H., primary, Sanchez, James F., primary, Yang, Lu, primary, Brown, Christine E., primary, Pichiorri, Flavia, primary, Htut, Myo, primary, Krishnan, Amrita Y., primary, and Forman, Stephen J., primary

Published
2023
Full Text
View/download PDF

19. Supplementary methods from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

Author

Brown, Christine E., primary, Badie, Behnam, primary, Barish, Michael E., primary, Weng, Lihong, primary, Ostberg, Julie R., primary, Chang, Wen-Chung, primary, Naranjo, Araceli, primary, Starr, Renate, primary, Wagner, Jamie, primary, Wright, Christine, primary, Zhai, Yubo, primary, Bading, James R., primary, Ressler, Julie A., primary, Portnow, Jana, primary, D'Apuzzo, Massimo, primary, Forman, Stephen J., primary, and Jensen, Michael C., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 2 from RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma

Author

Chen, Xuebo, primary, Zhang, Leying, primary, Zhang, Ian Y., primary, Liang, Junling, primary, Wang, Huaqing, primary, Ouyang, Mao, primary, Wu, Shihua, primary, da Fonseca, Anna Carolina Carvalho, primary, Weng, Lihong, primary, Yamamoto, Yasuhiko, primary, Yamamoto, Hiroshi, primary, Natarajan, Rama, primary, and Badie, Behnam, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 1 from RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma

Author

Chen, Xuebo, primary, Zhang, Leying, primary, Zhang, Ian Y., primary, Liang, Junling, primary, Wang, Huaqing, primary, Ouyang, Mao, primary, Wu, Shihua, primary, da Fonseca, Anna Carolina Carvalho, primary, Weng, Lihong, primary, Yamamoto, Yasuhiko, primary, Yamamoto, Hiroshi, primary, Natarajan, Rama, primary, and Badie, Behnam, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 1 from RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma

Author

Chen, Xuebo, primary, Zhang, Leying, primary, Zhang, Ian Y., primary, Liang, Junling, primary, Wang, Huaqing, primary, Ouyang, Mao, primary, Wu, Shihua, primary, da Fonseca, Anna Carolina Carvalho, primary, Weng, Lihong, primary, Yamamoto, Yasuhiko, primary, Yamamoto, Hiroshi, primary, Natarajan, Rama, primary, and Badie, Behnam, primary

Published
2023
Full Text
View/download PDF

25. Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma

Author

Brown, Christine E, Rodriguez, Analiz, Palmer, Joycelynne, Ostberg, Julie R, Naranjo, Araceli, Wagner, Jamie R, Aguilar, Brenda, Starr, Renate, Weng, Lihong, Synold, Timothy W, Tran, Vivi, Wang, Shelley, Reik, Andreas, D’Apuzzo, Massimo, Ressler, Julie A, Zhou, Yuanyue, Mendel, Matthew, Gregory, Philip D, Holmes, Michael C, Tang, Winson W, Forman, Stephen J, Jensen, Michael C, and Badie, Behnam

Subjects
Cancer Research, Oncology, T-Lymphocytes, Clinical Investigations, Interleukin-13 Receptor alpha2 Subunit, Humans, Steroids, Neurology (clinical), Glioblastoma, Glucocorticoids, Immunotherapy, Adoptive, Xenograft Model Antitumor Assays, Dexamethasone
Abstract

Background Wide-spread application of chimeric antigen receptor (CAR) T cell therapy for cancer is limited by the current use of autologous CAR T cells necessitating the manufacture of individualized therapeutic products for each patient. To address this challenge, we have generated an off-the-shelf, allogeneic CAR T cell product for the treatment of glioblastoma (GBM), and present here the feasibility, safety, and therapeutic potential of this approach. Methods We generated for clinical use a healthy-donor derived IL13Rα2-targeted CAR+ (IL13-zetakine+) cytolytic T-lymphocyte (CTL) product genetically engineered using zinc finger nucleases (ZFNs) to permanently disrupt the glucocorticoid receptor (GR) (GRm13Z40-2) and endow resistance to glucocorticoid treatment. In a phase I safety and feasibility trial we evaluated these allogeneic GRm13Z40-2 T cells in combination with intracranial administration of recombinant human IL-2 (rhIL-2; aldesleukin) in six patients with unresectable recurrent GBM that were maintained on systemic dexamethasone (4-12 mg/day). Results The GRm13Z40-2 product displayed dexamethasone-resistant effector activity without evidence for in vitro alloreactivity. Intracranial administration of GRm13Z40-2 in four doses of 108 cells over a two-week period with aldesleukin (9 infusions ranging from 2500–5000 IU) was well tolerated, with indications of transient tumor reduction and/or tumor necrosis at the site of T cell infusion in four of the six treated research subjects. Antibody reactivity against GRm13Z40-2 cells was detected in the serum of only one of the four tested subjects. Conclusions This first-in-human experience establishes a foundation for future adoptive therapy studies using off-the-shelf, zinc-finger modified, and/or glucocorticoid resistant CAR T cells.

Published
2022

26. Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Author

Du, Juan, primary, Fu, Weijun, additional, Lu, Jing, additional, Qiang, Wanting, additional, He, Haiyan, additional, Liu, Jin, additional, Yang, Ying, additional, Feng, Zhongyuan, additional, Jin, Lina, additional, Fan, Xiaoqiang, additional, Liu, Jia, additional, Zhang, Qi, additional, Shen, Lianjun, additional, Weng, Lihong, additional, and Cao, Wei, additional

Published
2022
Full Text
View/download PDF

27. Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).

Author

Du, Juan, primary, Jiang, Hua, additional, Dong, Baoxia, additional, Gao, Li, additional, Liu, Li, additional, Ge, Jian, additional, He, Aili, additional, Li, Lu, additional, Lu, Jing, additional, Chen, Xiequn, additional, Sersch, Martina A., additional, Zhao, Yi, additional, Shen, Lianjun, additional, Weng, Lihong, additional, Zhang, Hua, additional, Liu, Jia, additional, and Fu, Weijun, additional

Published
2022
Full Text
View/download PDF

28. CAR T cell therapy drives endogenous locoregional T cell dynamics in a responding patient with glioblastoma

Author

Jonsson, Vanessa D., primary, Ng, Rachel H., additional, Dullerud, Natalie, additional, Wong, Robyn A., additional, Hibbard, Jonathan, additional, Wang, Dongrui, additional, Aguilar, Brenda, additional, Starr, Renate, additional, Weng, Lihong, additional, Alizadeh, Darya, additional, Forman, Stephen J., additional, Badie, Behnam, additional, and Brown, Christine E., additional

Published
2021
Full Text
View/download PDF

30. Efficacy and Safety of First-Generation EGFR-TKIs Combined with Chemotherapy for Treatment-Naïve Advanced Non-Small-Cell Lung Cancer Patients Harboring Sensitive EGFR Mutations: A Single-Center, Open-Label, Single-Arm, Phase II Clinical Trial

Author

Lin,Jinghui, Li,Meifang, Chen,Shijie, Weng,Lihong, He,Zhiyong, Lin,Jinghui, Li,Meifang, Chen,Shijie, Weng,Lihong, and He,Zhiyong

Abstract

Jinghui Lin, Meifang Li, Shijie Chen, Lihong Weng, Zhiyong He Department of Thoracic Medical Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou City, Fujian Province, 350014, People’s Republic of ChinaCorrespondence: Zhiyong HeDepartment of Thoracic Medical Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No. 420 Fuma Road, Fuzhou City, Fujian Province, 350014, People’s Republic of ChinaEmail zhiyonghecn@sina.comPurpose: This single-center, open-label, single-arm, phase II clinical trial aimed to examine the efficacy and safety of the first-generation EGFR-TKIs combined with chemotherapy among treatment-naïve advanced non-small-cell lung cancer (NSCLC) patients harboring sensitive EGFR mutations.Materials and Methods: Patients with advanced EGFR-mutant NSCLC were given concurrent gefitinib (250 mg orally daily) and 3-week cycle of carboplatin plus pemetrexed for 4 to 6 cycles, followed by gefitinib maintenance until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety. This trial was registered at ClinicalTrials.gov (NCT02886195).Results: Of the 21 patients enrolled in this study, a 76.2% ORR and 100% DCR were observed and a higher ORR was seen in patients with EGFR 21L858R mutations than in those with 19del mutations (P = 0.012). The subjects had a median PFS of 15.0 months and a median OS of 26.0 months, and numerically longer PFS was seen in patients with EGFR 21L858R mutations than in those with 19del mutations (P = 0.281). There were 15 NSCLC patients without cerebral metastases at baseline, with 4 cases developing cerebral metastases during the treatment, and the 6-, 12- and 24-month cumulative incidence rates of the central nervous system metastasis were 6.67%, 13.3% and 26.7%, respectively. There

Published
2021

32. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma

Author

Wang, Xiuli, primary, Huynh, Christian, additional, Urak, Ryan, additional, Weng, Lihong, additional, Walter, Miriam, additional, Lim, Laura, additional, Vyas, Vibhuti, additional, Chang, Wen-Chung, additional, Aguilar, Brenda, additional, Brito, Alfonso, additional, Sarkissian, Aniee, additional, Bandara, N. Achini, additional, Yang, Lu, additional, Wang, Jinhui, additional, Wu, Xiwei, additional, Zhang, Jianying, additional, Priceman, Saul J., additional, Qin, Hong, additional, Kwak, Larry W., additional, Budde, Lihua E., additional, Thomas, Sandra H., additional, Clark, Mary C., additional, Popplewell, Leslie, additional, Siddiqi, Tanya, additional, Brown, Christine E., additional, and Forman, Stephen J., additional

Published
2021
Full Text
View/download PDF

33. Robust Localization for Intelligent Vehicles Based on Pole-Like Features Using the Point Cloud.

Author

Li, Liang, Yang, Ming, Weng, Lihong, and Wang, Chunxiang

Subjects
POINT cloud, FEATURE extraction, TRAFFIC signs & signals, TREE trunks, FOOTBRIDGES, AUTONOMOUS vehicles
Abstract

Localization in the complex urban environment is an open problem for current methods. The occlusion from dynamic objects, such as vehicles and pedestrians, degenerates the precision of the localization result. This article proposes a pole-like feature-based localization framework to solve this problem. Pole-like objects, such as posts of lamps or traffic sign and tree trunks, widely exist in the urban environment and are robust to occlusion, as they are usually higher than the objects on the road. First, this type of feature is extracted from the point cloud by a robust clustering algorithm. Then, the features from different frames of data are stitched to generate a feature map. For online localization, a Monte Carlo localization (MCL) framework is used to fuse the vehicle motion data and the map-matching result. An improved version of iterative closest point (ICP) that is specifically designed for the pole-like feature association is used for map matching based on the state of every particle. With the MCL scheme, localization is robust to the local minimum or robot kidnapping problem. Experimental results in the real urban environment demonstrate the precision and robustness of the proposed method, with mean absolute errors less than 0.20 m and 0.5°. The results also show that the proposed method outperforms some state-of-the-art localization methods in the complex urban environment. Note to Practitioners—There are some works using features from the 3-D point cloud, e.g., corners, planes, and reflectance, for robot localization. Instead of the abstract features, this article presents an object-feature-based localization scheme. We propose a novel pole-like object extraction algorithm based on the spatial distribution of the 3-D points. This algorithm can extract most types of pole-like objects in the urban environment. As these objects are highly distinct from other types of objects in their surroundings, localization is achieved by associating the pole-like features in the map and the features detected in real time through maximizing the likelihood. The whole system is verified with data collected in the real world, which indicates that its accuracy can fulfill the requirements of autonomous driving. The limitation of the proposed method is that it highly depends on one specific type of feature, which may not work well in the rural environment. In future research, we will address this problem by incorporating more types of semantic features for localization. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

36. P855 High-resolution maps of heterogeneous antigen expression in glioblastoma and implications for immunotherapy

Author

Barish, Michael, primary, Weng, Lihong, additional, Awabdeh, Dina, additional, Brewster, Blake, additional, D’Apuzzo, Massimo, additional, Zhai, Yubo, additional, Brito, Alfonso, additional, Chang, Brenda, additional, Sarkissian, Annie, additional, Starr, Renate, additional, Chang, Wen-Chung, additional, Aguilar, Brenda, additional, Naranjo, Araceli, additional, Blanchard, Suzette, additional, Rockne, Russell, additional, Badie, Behnam, additional, Jonsson, Vanessa, additional, Forman, Stephen, additional, Brown, Christine, additional, and Barish, Michael, additional

Published
2020
Full Text
View/download PDF

40. Abstract A045: Chlorotoxin redirects T-cells for specific and effective targeting against glioblastomas

Author

Wang, Dongrui, primary, Jonsson, Vanessa, additional, Wright, Sarah, additional, Chang, Wen-Chung, additional, Yang, Xin, additional, Starr, Renate, additional, Brito, Alfonso, additional, Aguilar, Brenda, additional, Sarkissian, Aniee, additional, Weng, Lihong, additional, Forman, Stephen J, additional, Barish, Michael E, additional, and Brown, Christine E., additional

Published
2019
Full Text
View/download PDF

41. The Cerebroventricular Environment Reprograms Locally Infused CAR T Cells for Superior Activity Against Both CNS and Systemic B Cell Lymphoma

Author

Wang, Xiuli, primary, Huynh, Christian, additional, Urak, Ryan, additional, Walter, Miriam, additional, Weng, Lihong, additional, Lim, Laura, additional, Vyas, Vibhuti, additional, Aguilar, Brenda, additional, Brito, Alfonso, additional, Sarkissian, Aniee, additional, Bandara, Achini, additional, Budde, Elizabeth E, additional, Popplewell, Leslie, additional, Siddiqi, Tanya, additional, Brown, Christine, additional, and Forman, Stephen J, additional

Published
2018
Full Text
View/download PDF

42. IMMU-09. HETEROGENEOUS INTRA-TUMORAL ANTIGEN EXPRESSION IN RELATION TO IMMUNOTHERAPY OF HIGH GRADE GLIOMA

Author

Barish, Michael, primary, Weng, Lihong, additional, D’Apuzzo, Massimo, additional, Zhai, Yubo, additional, Brito, Alfonso, additional, Chang, Brenda, additional, Sarkissian, Aniee, additional, Starr, Renate, additional, Chang, Wen-Chung, additional, Aguilar, Brenda, additional, Naranjo, Araceli, additional, Blanchard, Suzette, additional, Rockne, Russell, additional, Badie, Behnam, additional, Jonsson, Vanessa, additional, Awabdeh, Dina, additional, Brewster, Blake, additional, Forman, Stephen, additional, and Brown, Christine, additional

Published
2018
Full Text
View/download PDF

46. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma

Author

Brown, Christine E., primary, Aguilar, Brenda, additional, Starr, Renate, additional, Yang, Xin, additional, Chang, Wen-Chung, additional, Weng, Lihong, additional, Chang, Brenda, additional, Sarkissian, Aniee, additional, Brito, Alfonso, additional, Sanchez, James F., additional, Ostberg, Julie R., additional, D’Apuzzo, Massimo, additional, Badie, Behnam, additional, Barish, Michael E., additional, and Forman, Stephen J., additional

Published
2018
Full Text
View/download PDF

47. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma

Author

Wang, Xiuli, primary, Walter, Miriam, additional, Urak, Ryan, additional, Weng, Lihong, additional, Huynh, Christian, additional, Lim, Laura, additional, Wong, ChingLam W., additional, Chang, Wen-Chung, additional, Thomas, Sandra H., additional, Sanchez, James F., additional, Yang, Lu, additional, Brown, Christine E., additional, Pichiorri, Flavia, additional, Htut, Myo, additional, Krishnan, Amrita Y., additional, and Forman, Stephen J., additional

Published
2018
Full Text
View/download PDF

48. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer

Author

Priceman, Saul J., primary, Gerdts, Ethan A., additional, Tilakawardane, Dileshni, additional, Kennewick, Kelly T., additional, Murad, John P., additional, Park, Anthony K., additional, Jeang, Brook, additional, Yamaguchi, Yukiko, additional, Yang, Xin, additional, Urak, Ryan, additional, Weng, Lihong, additional, Chang, Wen-Chung, additional, Wright, Sarah, additional, Pal, Sumanta, additional, Reiter, Robert E., additional, Wu, Anna M., additional, Brown, Christine E., additional, and Forman, Stephen J., additional

Published
2017
Full Text
View/download PDF

50. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

Author

Brown, Christine E., primary, Alizadeh, Darya, additional, Starr, Renate, additional, Weng, Lihong, additional, Wagner, Jamie R., additional, Naranjo, Araceli, additional, Ostberg, Julie R., additional, Blanchard, M. Suzette, additional, Kilpatrick, Julie, additional, Simpson, Jennifer, additional, Kurien, Anita, additional, Priceman, Saul J., additional, Wang, Xiuli, additional, Harshbarger, Todd L., additional, D’Apuzzo, Massimo, additional, Ressler, Julie A., additional, Jensen, Michael C., additional, Barish, Michael E., additional, Chen, Mike, additional, Portnow, Jana, additional, Forman, Stephen J., additional, and Badie, Behnam, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results